News

The new program will focus on a specific drug target proposed by Merck, and Alnylam will proceed with preclinical development of an RNAi therapeutic for this target. The

Under the terms of the collaboration, Nektar will be responsible for formulation of the dry powder and development of the inhalation system, as well as clinical and commercial

An initial research collaboration agreement gave Schering exclusive marketing rights in Europe, while Novartis held corresponding rights for North America. Under the new agreement, Schering and Novartis will

ND7001 acts on a new target that has never been associated with depression or anxiety. It is the first representative of a new generation of psycho-active compounds potentially

Zelos is currently developing an injectable form of Ostabolin-C for the treatment of osteoporosis and has completed three phase I clinical trials. Parathyroid hormone (PTH) compounds are considered

In addition, Genzyme filed a motion for preliminary injunction to immediately seize and destroy all Gene-Activated glucocerebrosidase (GA-GCB) being used to treat patients in TKT’s ongoing clinical trial

Earlier in January, Ranbaxy announced that it had begun filing data for its range of anti-retrovirals (ARVs) with the FDA under its expedited review process for the US

Tipifarnib, administered orally, is being investigated in patients 65 years of age and older with newly diagnosed acute myeloid leukemia (AML). As a drug intended to treat a

The company’s major shareholder, Charter Pacific Corporation Limited continued its support by participating in the placement and maintains its holding at 20.1%. Two of the company’s other major